Akeega is a drug owned by Janssen Biotech Inc. It is protected by 11 US drug patents filed from 2023 to 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 27, 2038. Details of Akeega's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US11673877 | Niraparib compositions |
Mar, 2038
(13 years from now) | Active |
| US11091459 | Niraparib compositions |
Mar, 2038
(13 years from now) | Active |
| US8071623 | Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors |
Mar, 2031
(6 years from now) | Active |
| US8436185 | Pharmaceutically acceptable salts of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide |
Apr, 2029
(4 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11986468 | Methods of treating prostate cancer |
Jul, 2037
(12 years from now) | Active |
| US11992486 | Methods of treating prostate cancer |
Jul, 2037
(12 years from now) | Active |
| US11207311 | Method of treating prostate cancer |
Jul, 2037
(12 years from now) | Active |
| US11986469 | Methods of treating prostate cancer |
Jul, 2037
(12 years from now) | Active |
| US8859562 | Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer |
Aug, 2031
(6 years from now) | Active |
| US8143241 | DNA damage repair inhibitors for treatment of cancer |
Aug, 2027
(2 years from now) | Active |
| US8071579 | DNA damage repair inhibitors for the treatment of cancer |
Aug, 2027
(2 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Akeega's patents.
Latest Legal Activities on Akeega's Patents
Given below is the list of recent legal activities going on the following patents of Akeega.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 14 Sep, 2023 | US8143241 |
| Recordation of Patent eGrant | 13 Jun, 2023 | US11673877 |
| Patent eGrant Notification | 13 Jun, 2023 | US11673877 |
| Email Notification Critical | 13 Jun, 2023 | US11673877 |
| Electronic Review Critical | 13 Jun, 2023 | US11673877 |
| Patent Issue Date Used in PTA Calculation Critical | 13 Jun, 2023 | US11673877 |
| Recordation of Patent Grant Mailed Critical | 13 Jun, 2023 | US11673877 |
| Mail Patent eGrant Notification | 13 Jun, 2023 | US11673877 |
| Email Notification Critical | 25 May, 2023 | US11673877 |
| Electronic Review Critical | 25 May, 2023 | US11673877 |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Akeega and ongoing litigations to help you estimate the early arrival of Akeega generic.
Akeega's Litigations
Akeega been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 11, 2011, against patent number US8859562. The petitioner , challenged the validity of this patent, with Thomas Helleday as the respondent. Click below to track the latest information on how companies are challenging Akeega's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8859562 | October, 2011 |
Decision
(25 Mar, 2014) | Thomas Helleday | |
FDA has granted some exclusivities to Akeega. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Akeega, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Akeega.
Exclusivity Information
Akeega holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2026. Details of Akeega's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 11, 2026 |
Several oppositions have been filed on Akeega's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Akeega's generic, the next section provides detailed information on ongoing and past EP oppositions related to Akeega patents.
Akeega's Oppositions Filed in EPO
Akeega has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Apr 13, 2012, by Adams, Harvey Vaughan John. This opposition was filed on patent number EP04743564A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP04798705A | May, 2012 | STRAWMAN LIMITED | Opposition procedure closed |
| EP04798705A | May, 2012 | Adams, Harvey Vaughan John | Opposition procedure closed |
| EP04743564A | Apr, 2012 | STRAWMAN LIMITED | Patent maintained as amended |
| EP04743564A | Apr, 2012 | Adams, Harvey Vaughan John | Patent maintained as amended |
US patents provide insights into the exclusivity only within the United States, but Akeega is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Akeega's family patents as well as insights into ongoing legal events on those patents.
Akeega's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Akeega's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Mar 27, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Akeega Generics:
There are no approved generic versions for Akeega as of now.
Alternative Brands for Akeega
Akeega which is used for treating metastatic castration-resistant prostate cancer associated with a deleterious BRCA mutation., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Pharmaand |
| |||
About Akeega
Akeega is a drug owned by Janssen Biotech Inc. It is used for treating metastatic castration-resistant prostate cancer associated with a deleterious BRCA mutation. Akeega uses Abiraterone Acetate; Niraparib Tosylate as an active ingredient. Akeega was launched by Janssen Biotech in 2023.
Approval Date:
Akeega was approved by FDA for market use on 11 August, 2023.
Active Ingredient:
Akeega uses Abiraterone Acetate; Niraparib Tosylate as the active ingredient. Check out other Drugs and Companies using Abiraterone Acetate; Niraparib Tosylate ingredient
Treatment:
Akeega is used for treating metastatic castration-resistant prostate cancer associated with a deleterious BRCA mutation.
Dosage:
Akeega is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 500MG;EQ 50MG BASE | TABLET | Prescription | ORAL |
| 500MG;EQ 100MG BASE | TABLET | Prescription | ORAL |